FDANonrulemakingFDA-2025-D-3217

Who commented on this docket

Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products; Draft Guidance for Industry; Availability

10 organizations filed 10 public comments on Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products; Draft Guidance for Industry; Availability, at the Food and Drug Administration. The comment window closed 137d ago.

Organizations
10
Comments
10
RIN
Comment window
closed 137d ago

Abstract

Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products; Draft Guidance for Industry; Availability

Commenters (10)

  • American Academy of Pediatrics (AAP)
    1 filing · confidence 97%
  • American Association for Cancer Researchtrade assoc.
    1 filing · confidence 85%
  • CPAC Foundation Center for Regulatory Freedomtrade assoc.
    1 filing · confidence 85%
  • Critical Path Institutetrade assoc.
    1 filing · confidence 85%
  • Duke-Robert J. Margolis Institute for Health Policytrade assoc.
    1 filing · confidence 85%
  • European Federation of Statisticians in the Pharmaceutical Industrytrade assoc.
    1 filing · confidence 85%
  • Insmed Incorporatedunverified attribution
    1 filing · confidence 70%
  • International Society of Pharmacoepidemiologytrade assoc.
    1 filing · confidence 85%
  • Pediatric Inclusion Alliancetrade assoc.
    1 filing · confidence 85%
  • Presentient Technologiesunverified attribution
    1 filing · confidence 70%
View this docket on regulations.gov →

Attribution is name-based and imperfect. regulations.gov data is public record.